Medical Cannabis for Multiple Sclerosis UK

Multiple sclerosis (MS) is one of the few conditions for which a cannabis-based medicine holds a full MHRA licence in the United Kingdom. For the estimated 130,000 people living with MS in the UK, medical cannabis — and Sativex in particular — represents a well-evidenced treatment option for specific symptoms, particularly spasticity. This guide covers the full picture: what the evidence shows, what is available on prescription and how to access it.

Spasticity, Sativex and the NICE Technology Appraisal

Spasticity — uncontrolled muscle stiffness and spasms — affects up to 80 per cent of people with MS at some point in their illness. It causes pain, disrupts sleep, limits mobility and significantly reduces quality of life. Conventional treatments including baclofen, tizanidine and physiotherapy help many patients, but a substantial proportion continue to experience problematic spasticity despite optimised conventional treatment.

Sativex (nabiximols) is an oromucosal spray containing a standardised extract of cannabis — 2.7mg THC and 2.5mg CBD per actuation — licensed by the MHRA specifically for the treatment of moderate to severe spasticity in adults with MS who have not responded adequately to other anti-spasticity medications. It is administered by spraying under the tongue or inside the cheek, with typical doses of four to twelve sprays per day.

NICE Technology Appraisal TA609 (2019) recommends Sativex as a clinically and cost-effective option for MS-related spasticity in this population. It is therefore available on NHS prescription via specialist neurologists, making it the most accessible cannabis-based medicine in the UK healthcare system. Patients whose neurologist confirms inadequate response to baclofen and tizanidine can be referred for a supervised Sativex trial.

Find a UK licensed clinic with MS expertise if you are considering private prescription outside of the NHS pathway.

Pain, Bladder Issues and Sleep Disruption in MS

Spasticity is not the only symptom of MS that may respond to cannabinoid therapy. MS-related central neuropathic pain — characterised by burning, stabbing or pressure sensations — affects around half of all people with MS and is notoriously difficult to treat with conventional analgesics. The same CB1-mediated mechanisms that underlie Sativex's anti-spasticity effects are relevant for neuropathic pain, and several observational studies and patient surveys report significant pain relief with CBPM use.

Bladder dysfunction, particularly overactive bladder with urgency and frequency, affects the majority of MS patients. There is growing clinical interest in cannabinoid therapy for bladder symptoms, based on the presence of cannabinoid receptors in bladder smooth muscle and the urothelium. While evidence remains limited in this area compared to spasticity, some UK neurologists now consider CBPMs for refractory MS-related bladder symptoms as part of a specialist referral pathway.

Sleep disruption in MS is multifactorial: pain, spasticity, bladder urgency and fatigue all disrupt normal sleep architecture. THC-dominant and balanced cannabinoid products have shown benefit for sleep in MS across multiple small trials and real-world patient series. A typical approach involves a Sativex spray or equivalent CBPM in the evening to address spasticity and pain, with improved sleep as a secondary benefit. You can compare prices on evening formulations available through UK pharmacies.

Private Prescription Access for MS Patients in the UK

While Sativex is theoretically available on the NHS, many MS patients face practical barriers: not all neurologists are comfortable prescribing it, commissioning decisions vary by Integrated Care Board, and some patients do not meet the strict trial criteria. Private prescription provides an alternative route.

UK private clinics including Mamedica, Lyphe and Releaf have MS experience within their clinical teams, typically neurologists or pain specialists. A private prescription for an MS patient would typically involve:

• Review of existing neurology letters and MRI reports confirming the MS diagnosis.
• Documentation of prior treatment attempts with at least two anti-spasticity agents.
• Initial consultation with a GMC-registered specialist costing £75 to £199 depending on clinic.
• A supervised titration period, starting at low doses and building up over four to eight weeks.

Monthly private prescription costs for Sativex or equivalent products typically range from £150 to £350, depending on dose and pharmacy. For patients with stable MS who have found an effective regime, some clinics offer reduced-cost follow-up packages. Explore qualifying conditions to understand what documentation is typically needed before your first appointment.

Fatigue, Cognition and Quality of Life in MS

Fatigue is the most commonly reported symptom in MS, affecting more than 80 per cent of patients, and it is one of the most difficult to treat effectively. Conventional treatments such as amantadine and modafinil offer modest benefit for some patients. The role of medical cannabis in MS-related fatigue is nuanced: THC can induce sedation and worsen cognitive fog in some patients, particularly at higher doses, while CBD may have a mild energising effect at lower doses and potentially beneficial effects on neuroinflammatory processes thought to contribute to MS fatigue.

Cognitive symptoms, including slowed processing speed, attention difficulties and memory problems, are present in up to 65 per cent of people with MS. High-THC products may exacerbate these symptoms acutely, which is why UK neurologists prescribing for MS patients typically start with lower-THC or balanced formulations and monitor cognitive function closely. Patients who report worsening of cognitive symptoms during the titration phase are usually advised to reduce the THC dose or switch to a higher-CBD product.

Despite these caveats, multiple quality-of-life studies in MS patients using Sativex or equivalent CBPMs report improvements in overall wellbeing, reduced pain scores, better sleep quality and improved social functioning. For many patients, the combination of spasticity relief, pain reduction and sleep improvement produces a cumulative quality-of-life benefit that outweighs any cognitive side effects at a well-titrated dose. UK clinics managing MS patients with CBPMs generally recommend six-monthly or annual patient-reported outcome reviews using validated tools such as the MS Quality of Life-54 questionnaire.